MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug Designation Advancing Ultra-Rare Neuromuscular Disease Therapies · GlobeNewswire Inc. New York, Oct. 24, 2024 ...
MDA's 75-year progress includes gene discoveries and drug approvals for DMD and SMA, emphasizing the importance of sustained research funding. Advocacy efforts target Medicaid coverage, newborn ...
MDA's 75th meeting will focus on integrating clinical and research efforts, highlighting muscle and neuroregeneration, and gene therapy advancements. Sessions will explore the administration of ...
The Muscular Dystrophy Association (MDA)’s Venture Philanthropy arm has injected $1.2 million into Valerion Therapeutics’ myotubular myopathy (MTM) pipeline, funding the firm to continue its ...
The Muscular Dystrophy Association (MDA)’s Kickstart program has announced receipt of both U.S. orphan drug and rare pediatric disease designations in support of work for congenital myasthenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results